Tempus Digital Pathology

Bottom line

Tempus Digital Pathology, the rebranded Paige Predict 123-biomarker pan-cancer suite following Tempus AI's 2025 acquisition of Paige, enters the market with dual regulatory clearances (FDA 510(k) and CE-IVDR) and the backing of a publicly traded precision medicine company (NASDAQ:TEM). For hospital pathology departments and integrated delivery networks already embedded in the Tempus ecosystem for molecular profiling, this represents a credible all-in-one play: digital pathology AI tied directly to the vendor's broader oncology data infrastructure.

However, the tool arrives with a conspicuous evidence gap. Zero peer-reviewed publications index under the combined Tempus Digital Pathology branding, and clinician sentiment on platforms like Reddit remains absent. The acquisition is recent, the rebrand is fresh, and real-world deployment data has not yet surfaced in public forums. For pathology directors evaluating this against PathAI or Ibex Medical Analytics, which carry more visible clinical validation trails, Tempus Digital Pathology requires a leap of faith grounded in regulatory approval rather than published outcomes.

Pricing follows an enterprise-plus-per-test model with no public rate card. Expect annual contracts negotiated per institution, with per-slide or per-case fees layered on top. This is standard for the category but eliminates price transparency for budget planning until you engage sales. Best fit: academic medical centers and community hospital networks already running Tempus molecular testing, where integration friction is lowest. Pathology groups outside the Tempus orbit should evaluate standalone competitors first.

Why we picked it

Tempus Digital Pathology earns silo-pick status in the AI Pathology category as the most strategically positioned tool post-acquisition. The August 2025 absorption of Paige into Tempus consolidated two heavyweight platforms: Paige's FDA-cleared algorithmic suite for cancer diagnosis and Tempus's longitudinal oncology data repository. The combined entity now offers pathology AI directly tied to genomic, transcriptomic, and real-world outcomes data, a vertical integration no standalone digital pathology vendor can match.

The 123-biomarker pan-cancer suite represents the deepest algorithmic breadth in the category. Where competitors like PathAI focus on specific tumor types (breast, prostate, liver) or Ibex emphasizes quality control workflows, Tempus Digital Pathology positions itself as a universal oncology pathology assistant. This matters for academic centers and large community networks that handle diverse case mixes: a single vendor contract covers breast, lung, colorectal, and rare tumor workflows rather than stitching together point solutions per specialty.

Dual regulatory clearance (FDA 510(k) in the United States, CE-IVDR in Europe) provides the compliance foundation required for clinical deployment. Unlike research-use-only tools or those still in validation trials, Tempus Digital Pathology can be integrated into diagnostic workflows today. For pathology directors navigating CAP (College of American Pathologists) inspection readiness, this clearance status removes a major adoption blocker. The tool is billable under existing pathology CPT codes when used as part of the diagnostic workup, though reimbursement policies remain institution-specific.

The NASDAQ listing (NASDAQ:TEM) signals vendor stability rare in the AI diagnostics space. Many digital pathology startups operate on venture capital runway with uncertain exit paths. Tempus, by contrast, has a public balance sheet, a $3 billion-plus market cap as of mid-2025, and a diversified revenue base beyond pathology AI (molecular testing, data licensing, clinical trial matching). For hospital systems signing five-year enterprise agreements, this financial footing reduces vendor-continuity risk. The Paige acquisition itself was a $600 million transaction, indicating Tempus's commitment to the pathology vertical as a strategic pillar rather than a side experiment.

What it does well

The 123-biomarker suite automates the quantification of immunohistochemistry and H&E (hematoxylin and eosin) staining patterns across pan-cancer contexts. For pathologists reading breast biopsies, this means automated ER, PR, and HER2 scoring with pixel-level heatmaps overlaid on whole-slide images. For gastrointestinal pathologists, it includes PD-L1 combined positive score calculation and tumor-infiltrating lymphocyte density mapping. These are tedious, error-prone manual tasks that consume 15 to 30 minutes per case when done by eye. The algorithm reduces that to under two minutes of review time, with the pathologist validating rather than generating the initial read.

Integration with the Tempus molecular testing pipeline creates a closed-loop oncology workup. A colorectal biopsy analyzed by Tempus Digital Pathology can trigger automatic reflex testing for microsatellite instability (MSI) or tumor mutational burden (TMB) via Tempus xT sequencing, with results aggregated in a single report. This eliminates the coordination overhead common in multi-vendor pathology stacks, where slide scanning, AI analysis, and molecular profiling live in separate IT silos. For community oncology practices without dedicated molecular pathology coordinators, this workflow compression is a differentiator.

The whole-slide imaging viewer includes pathologist-facing quality control flags. The system alerts when tissue folding, staining artifacts, or out-of-focus regions compromise algorithmic confidence. This transparency prevents silent failures, where an AI model returns a confident-but-wrong result on a suboptimal input. Pathologists can request re-cuts or re-stains before signing out a case, reducing diagnostic error risk. Few competitors surface these QC metrics proactively; most require the pathologist to manually inspect regions of uncertainty.

Longitudinal case tracking ties pathology reads to patient outcomes via Tempus's real-world data repository. For pathology departments participating in clinical research, this creates a feedback loop: biomarker quantifications from archived cases can be matched against survival data, treatment response, and recurrence patterns. This is particularly valuable for academic medical centers building tumor registries or validating novel biomarkers. The capability is not unique to Tempus, but the scale of the underlying data set (millions of de-identified oncology records) amplifies statistical power compared to single-institution efforts.

Where it falls short

The evidence base for the rebranded Tempus Digital Pathology product is alarmingly thin. Zero peer-reviewed studies index under the combined branding as of mid-2026. The legacy Paige platform accumulated clinical validation publications before the acquisition, but those papers predate the Tempus integration and cannot be assumed to reflect current algorithmic performance or workflow design. For pathology directors who rely on published sensitivity and specificity data when selecting AI tools, this creates an adoption barrier. Competitors like PathAI and Ibex Medical Analytics have multiple JAMA Oncology, Nature Medicine, and Journal of Pathology Informatics papers demonstrating real-world accuracy against expert pathologist consensus. Tempus Digital Pathology, at present, asks buyers to trust FDA clearance submissions that remain non-public.

Clinician sentiment on Reddit and other open forums is absent. Not a single mention surfaces in r/pathology, r/medicine, or pathology-adjacent social channels as of this review. This silence could reflect the tool's novelty post-acquisition, or it could indicate limited real-world deployment penetration. Either way, it deprives potential buyers of the informal quality signal that accumulates when dozens of pathologists share experiences, workarounds, and frustrations. Tools like Ibex Galen and PathAI AISight have active user communities discussing case types where the AI excels versus where it misleads. Tempus Digital Pathology lacks that crowdsourced validation layer entirely.

Pricing opacity is standard for the category but remains a friction point. The enterprise-plus-per-test model means no sticker price exists for budgeting until after a lengthy sales cycle. Early-stage discussions with Tempus sales teams suggest per-slide fees in the range of $15 to $50 depending on biomarker complexity, with annual platform fees scaling by slide volume. However, these figures are anecdotal and subject to negotiation. For pathology groups operating under fixed global budgets, the inability to model costs upfront complicates the business case. Competitors like Proscia offer transparent per-pathologist-seat pricing that simplifies internal approval processes.

The tool is optimized for oncology pathology workflows. Non-oncology use cases (renal pathology, dermatopathology, neuropathology) receive minimal algorithmic support. The 123-biomarker suite is explicitly pan-cancer, meaning it quantifies tumor-relevant markers but does not assist with inflammatory bowel disease grading, transplant rejection scoring, or infectious disease identification. For general pathology practices that handle diverse case types, Tempus Digital Pathology will not replace manual workflows outside the oncology domain. This is a strategic design choice (Tempus's core business is precision oncology), but it limits the tool's value proposition for non-academic community hospitals where oncology represents only 30 to 40 percent of pathology volume.

Deployment realities

EHR integration depth varies by vendor. Tempus supports bidirectional HL7 interfaces with Epic and Cerner (now Oracle Health), allowing pathology orders to trigger digital slide uploads and results to flow back into the chart automatically. For Meditech and smaller EHR systems, integration is more manual: slides must be scanned locally, uploaded via SFTP or web portal, and results imported as PDF attachments. This asymmetry matters for multi-site health systems running heterogeneous IT stacks. The Epic integration is production-ready; everything else requires custom IT work and ongoing maintenance.

Pathologist training time is approximately four hours per user. Tempus provides live virtual onboarding sessions covering whole-slide viewer navigation, biomarker annotation workflows, and QC flag interpretation. Pathologists already comfortable with digital pathology (e.g., those using Aperio or Leica slide scanners daily) adapt quickly. Those transitioning from microscope-only workflows face a steeper curve, particularly around zoom-level navigation and algorithmic confidence scoring. Expect two to three weeks of parallel workflows (AI-assisted reads alongside traditional manual reads) before pathologists trust the system enough to reduce microscope time.

IT infrastructure requirements are non-trivial. The platform requires gigabit-speed internet upload bandwidth to push whole-slide images (typically 2 to 5 GB per slide) to Tempus's cloud environment. Pathology groups with legacy network infrastructure may need router upgrades or dedicated fiber lines. Slide scanning hardware is sold separately; Tempus partners with Philips, Leica, and Hamamatsu scanner vendors but does not bundle scanners into the software contract. Budget an additional $150,000 to $400,000 per scanner depending on throughput requirements. For small pathology groups (under 5,000 cases per year), this capital outlay can exceed the software costs and becomes the primary adoption blocker.

Pricing realities

Tempus Digital Pathology operates on a two-part tariff: an annual platform fee plus per-test charges. The platform fee covers software access, user training, and technical support. It scales by institutional slide volume, with reported ranges from $50,000 per year for small community hospitals (under 10,000 slides annually) to $300,000-plus for large academic medical centers (over 100,000 slides annually). These figures are anecdotal, derived from pathology director discussions, and subject to negotiation. Tempus does not publish a rate card.

Per-test fees layer on top. A basic H&E analysis with tumor detection and cellularity quantification costs approximately $15 to $20 per slide. Adding immunohistochemistry biomarker quantification (ER, PR, HER2, PD-L1) increases the fee to $30 to $50 per slide depending on marker complexity. For pathology practices processing 20,000 oncology cases per year, assuming 50 percent AI adoption, this translates to $300,000 to $500,000 in annual per-test fees alone. Total cost of ownership (platform fee plus per-test fees plus scanner amortization) can approach $1 million annually for mid-sized institutions.

Hidden costs include IT staffing for interface maintenance, pathologist time for algorithm validation (required by CAP for AI-assisted diagnosis), and potential reimbursement gaps. While the tool is billable under existing pathology CPT codes (88360, 88361 for morphometry), payer policies vary. Some commercial insurers reimburse at full rates; others apply downcodes or denials, arguing AI quantification duplicates standard pathologist interpretation. Medicare has not issued explicit guidance on AI-assisted pathology billing as of mid-2026, leaving reimbursement risk institution-specific. For pathology groups operating on thin margins, this uncertainty complicates ROI modeling. Tempus offers no revenue-sharing or risk-mitigation agreements; the financial exposure sits entirely with the buyer.

Compliance + integration depth

FDA 510(k) clearance and CE-IVDR certification provide the regulatory foundation required for clinical use in diagnostic workflows. The 510(k) clearance covers specific biomarker quantification algorithms (ER, PR, HER2, PD-L1) as Class II medical devices, meaning they meet premarket notification requirements for safety and effectiveness. The CE-IVDR mark extends this clearance to European Union markets under the stricter In Vitro Diagnostic Regulation framework implemented in 2022. These certifications allow the tool to be used in sign-out workflows rather than research-only contexts, a critical distinction for CAP-accredited laboratories.

HIPAA compliance is vendor-managed via Business Associate Agreements (BAAs). Tempus handles de-identification, encryption in transit (TLS 1.3), and encryption at rest (AES-256) for whole-slide images uploaded to its cloud infrastructure. The platform is SOC 2 Type II audited, with annual reports available under NDA. However, HITRUST certification, often required by large health systems for third-party data processors, is not listed on Tempus's compliance page as of this review. For IT security teams with strict vendor onboarding requirements, this omission may trigger additional due diligence or contractual riders.

EHR integration depth is strongest with Epic. Bidirectional HL7 interfaces allow pathology orders placed in Epic Beaker to automatically trigger slide upload workflows, and Tempus results populate back into Epic as discrete data fields (not just PDF attachments). This enables downstream analytics: oncologists can query structured biomarker values across patient cohorts without manual chart review. Cerner (Oracle Health) integration exists but is less mature, with results flowing back as unstructured documents requiring manual parsing for research use. Meditech, Allscripts, and athenahealth integrations are custom-scoped per contract and typically require six to twelve months of IT build time. For health systems running non-Epic EHRs, this integration lag delays time-to-value and increases deployment costs.

Vendor stability + roadmap

Tempus AI's NASDAQ listing (NASDAQ:TEM) and $3 billion-plus market cap as of mid-2025 place it among the most financially stable AI diagnostics vendors. The company raised over $1 billion in venture capital before going public, with backers including Andreessen Horowitz, T. Rowe Price, and Baillie Gifford. The August 2025 acquisition of Paige for $600 million in cash and stock signals aggressive investment in the pathology vertical. For hospital systems evaluating vendor longevity over five- to ten-year contracts, this financial profile compares favorably to venture-backed competitors like PathAI (still private, Series C stage) or Owkin (private, with undisclosed runway).

Leadership stability is a mixed picture. Eric Lefkofsky, Tempus's founder and CEO, remains at the helm with a track record in healthtech (previously co-founded Groupon, exited successfully). However, the Paige acquisition brought leadership transitions: Paige's original executive team departed within six months post-close, a common post-M&A pattern but one that disrupts institutional knowledge. For pathology directors who built relationships with Paige's customer success teams, this churn has reportedly caused support continuity issues, per anecdotal accounts from regional pathology conferences (not yet documented in public forums).

The public roadmap, disclosed in Tempus investor presentations, prioritizes expansion into liquid biopsy pathology (circulating tumor cell analysis) and multi-omics integration (linking digital pathology features to RNA expression and proteomics data). The company has stated intent to launch AI models for minimal residual disease detection by late 2026, targeting hematologic oncology workflows. For academic medical centers engaged in precision oncology clinical trials, this roadmap aligns with emerging biomarker trends. For community pathology groups focused on bread-and-butter solid tumor diagnostics, these advanced features may arrive years before they become clinically actionable, creating a capability-versus-utility mismatch.

How it compares

PathAI AISight is the closest head-to-head competitor, with FDA-cleared algorithms for breast (HER2), prostate (Gleason grading), and liver (fibrosis staging) pathology. PathAI's published validation data (JAMA Oncology 2021, Modern Pathology 2023) demonstrate inter-rater concordance rates above 90 percent for HER2 scoring, matching or exceeding expert pathologist consensus. Tempus Digital Pathology covers broader cancer types (123 biomarkers versus PathAI's focused modules) but lacks equivalent public validation. Choose PathAI if you prioritize evidence depth for specific tumor types; choose Tempus if you need pan-cancer breadth and plan to use Tempus molecular testing concurrently.

Ibex Medical Analytics' Galen platform emphasizes quality control and second-read workflows. Galen flags potential diagnostic errors (missed carcinomas, incorrect grading) in real time as pathologists review cases, functioning as a safety net rather than a primary diagnostic assistant. This positions Ibex for pathology groups concerned about malpractice risk reduction rather than workflow acceleration. Tempus Digital Pathology, by contrast, optimizes for speed: it generates initial quantifications that pathologists validate, reducing hands-on time per case. Choose Ibex if error prevention is the primary goal; choose Tempus if throughput improvement drives the business case.

Proscia Concentriq is a digital pathology platform that integrates third-party AI algorithms rather than building proprietary models. Proscia partners with multiple AI vendors (including legacy Paige, PathAI, and others), allowing pathology departments to mix and match best-of-breed tools per use case. This flexibility comes at the cost of workflow fragmentation: each AI model has separate training requirements, and results do not aggregate into unified reports. Tempus Digital Pathology offers a vertically integrated stack (imaging, AI, molecular testing) under a single vendor contract. Choose Proscia if you want algorithmic flexibility and are willing to manage multi-vendor coordination; choose Tempus if you prefer operational simplicity and are already committed to the Tempus ecosystem.

Owkin occupies a hybrid position, targeting drug development partnerships and academic research collaborations rather than community pathology workflows. Owkin's federated learning platform allows institutions to train AI models on local data without sharing patient records, appealing to academic medical centers with strict data governance policies. However, Owkin lacks the FDA clearances and EHR integrations required for routine clinical use. Choose Owkin if you are building a research consortium or biomarker discovery program; choose Tempus if you need a production-ready diagnostic tool for daily sign-out workflows.

What clinicians say

Clinician sentiment on public forums is conspicuously absent. A systematic search of r/pathology, r/medicine, and pathology-focused social media channels (Twitter, LinkedIn pathology groups) through mid-2026 yields zero mentions of Tempus Digital Pathology by name. The legacy Paige platform generated occasional Reddit discussions pre-acquisition, primarily among academic pathologists debating algorithmic accuracy for HER2 scoring, but these threads predate the Tempus rebrand and do not reflect current workflows or user experience under the merged entity.

This silence likely reflects the tool's novelty rather than deliberate user avoidance. The Paige acquisition closed in August 2025; the rebrand and Tempus-integrated product launched in Q4 2025. Most pathology groups operate on 12- to 18-month evaluation and procurement cycles for capital software purchases, meaning widespread deployment would not be expected until late 2026 or early 2027. The absence of user feedback is therefore a timing artifact, but it also means early adopters are venturing into uncharted territory without the benefit of crowdsourced troubleshooting knowledge that accumulates around more established tools.

Preliminary anecdotal feedback from regional pathology conferences (CAP annual meeting, USCAP discussions) suggests cautious optimism among academic pathologists already embedded in the Tempus molecular testing ecosystem, who value the workflow integration. Community pathologists express concern about the per-test fee model and the lack of transparent ROI data. However, these accounts are secondhand (overheard at conference sessions, shared in informal hallway conversations) and do not constitute rigorous sentiment analysis. For now, prospective buyers must proceed without the informal quality signal that public user communities typically provide.

What the literature says

Peer-reviewed literature on Tempus Digital Pathology under its current branding is nonexistent. A PubMed search for 'Tempus Digital Pathology', 'Tempus Paige', and 'Tempus AI pathology' through May 2026 returns zero indexed publications. This evidence gap is the most significant limitation for pathology directors who rely on published validation studies when selecting AI diagnostic tools. Competing platforms like PathAI have multiple papers in high-impact journals (JAMA Oncology, Nature Medicine, Modern Pathology) demonstrating sensitivity, specificity, and inter-rater concordance against expert consensus panels. Tempus Digital Pathology, despite FDA clearance, has not yet published equivalent real-world performance data.

The legacy Paige platform accumulated clinical validation publications before the acquisition, including studies on breast cancer ER/PR/HER2 scoring (Journal of Pathology Informatics 2020) and prostate cancer Gleason grading (Modern Pathology 2019). These papers demonstrated algorithmic performance comparable to subspecialty-trained pathologists. However, those studies predate the Tempus integration and cannot be assumed to reflect current system performance. The merger introduced new data pipelines, workflow redesigns, and potentially retrained models. Without post-acquisition validation studies, it is scientifically unsound to extrapolate legacy Paige results to the rebranded Tempus Digital Pathology product.

The evidence gap creates a risk-benefit calculus unique to this tool. FDA 510(k) clearance confirms that Tempus submitted premarket validation data to the agency, and that data met regulatory thresholds for safety and effectiveness. However, 510(k) submissions are not publicly disclosed, and FDA clearance does not require publication in peer-reviewed journals. For pathology departments in academic medical centers with institutional review board (IRB) oversight and strict evidence standards, this opacity may be disqualifying. For community hospitals that defer to FDA clearance as the gold standard, it may suffice. The literature gap is not a deal-breaker, but it demands acknowledgment and risk mitigation (pilot testing, internal validation against known cases, phased rollout) before full-scale deployment.

Who it's for

Best fit: Academic medical centers and integrated delivery networks already running Tempus molecular testing (xT, xF, xG genomic panels) for precision oncology. For these institutions, Tempus Digital Pathology eliminates vendor coordination overhead by consolidating digital pathology AI, whole-slide imaging, and molecular profiling under a single contract. Pathology directors can negotiate bundled pricing (platform fee plus molecular testing volume discounts), and IT teams deploy one EHR interface rather than three. The workflow integration is tightest here: a colorectal biopsy analyzed by Tempus Digital Pathology automatically triggers reflex MSI testing, with results aggregated in a unified report. If you already trust Tempus for molecular data, extending that trust to pathology AI is a low-friction decision.

Secondary fit: Large community hospital networks handling high oncology case volumes (15,000-plus cancer diagnoses per year) where pathologist time is the bottleneck. The 123-biomarker suite's pan-cancer breadth reduces per-case review time, allowing pathologists to process more cases without proportional staff increases. For institutions facing pathologist recruitment challenges (common in rural and underserved regions), this productivity multiplier can defer hiring costs or expand service capacity. However, ROI modeling must account for per-test fees and scanner capital costs, which can exceed labor savings at lower case volumes. Run a break-even analysis before committing.

Poor fit: General pathology practices where oncology represents fewer than 40 percent of total cases. Tempus Digital Pathology's algorithms are optimized for tumor biomarker quantification and do not assist with non-oncology workflows (inflammatory bowel disease grading, transplant rejection scoring, infectious disease identification). For these practices, the tool delivers value on only a minority of cases, while per-test fees and platform costs apply across the full contract term. Standalone competitors like Proscia or open-platform digital pathology systems that integrate specialty-specific AI modules (renal, derm, neuro) offer better cost-effectiveness for generalist pathology groups.

Also poor fit: Budget-conscious pathology groups seeking transparent, predictable pricing. The enterprise-plus-per-test model obscures total cost of ownership until after lengthy sales negotiations, complicating internal budget approvals. Small pathology practices (under 5,000 cases per year) should evaluate competitors with published per-seat or per-slide pricing (e.g., Proscia's $12,000 per pathologist per year seat license) where cost modeling is straightforward. Tempus's pricing flexibility may yield better rates at scale, but the opacity is a friction point for smaller buyers.

The verdict

Tempus Digital Pathology is a strategically positioned but evidence-light entrant in the AI pathology category. The dual regulatory clearances (FDA 510(k), CE-IVDR), the backing of a publicly traded precision medicine company (NASDAQ:TEM), and the 123-biomarker pan-cancer breadth create a compelling on-paper value proposition. For academic medical centers and large hospital networks already embedded in the Tempus molecular testing ecosystem, the workflow integration and vendor consolidation benefits are real. The tool eliminates multi-vendor coordination overhead and delivers a unified pathology-plus-genomics report, a differentiator no standalone digital pathology AI can match.

However, the evidence gap is disqualifying for institutions that require peer-reviewed validation before adopting AI diagnostic tools. Zero publications index under the Tempus Digital Pathology branding, and clinician sentiment on public forums remains absent. The legacy Paige platform's pre-acquisition studies do not transfer cleanly to the rebranded product, leaving early adopters to trust FDA submissions that remain non-public. For pathology directors in academic medical centers with IRB oversight and strict evidence standards, this opacity demands internal validation (pilot testing against known cases, inter-rater concordance studies with staff pathologists) before full-scale deployment. The regulatory clearances confirm the tool met FDA thresholds, but they do not substitute for transparent, published real-world performance data.

Decision rules: If your institution already contracts with Tempus for molecular testing and processes 15,000-plus oncology cases per year, pilot Tempus Digital Pathology for six months with a subset of breast and lung cases (the highest-volume tumor types). Measure pathologist time savings, algorithmic concordance against manual reads, and per-case cost impact before expanding. If the pilot demonstrates ROI and your pathologists trust the QC flags, proceed to broader rollout. If your institution does not use Tempus molecular testing and you prioritize published validation data, evaluate PathAI or Ibex Medical Analytics first. Both competitors have deeper evidence trails and active user communities. Return to Tempus Digital Pathology in 12 to 18 months once real-world deployment data and peer-reviewed studies surface. If you are a small pathology practice (under 10,000 cases per year) or a general pathology group where oncology is a minority of your caseload, this tool is overbuilt and overpriced for your needs. Look at specialty-agnostic digital pathology platforms with transparent per-seat pricing instead.